---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-105923"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:13:23.097296+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HeartSciences reports Q1 FY2025 cash of $4.3M, raises $1.9M in non-dilutive debt; MyoVista device on track

## Summary
- Cash and cash equivalents of $4.3M as of July 31, 2024; shareholders' equity of $5.9M.
- Subsequent to quarter end, closed $1.9M net non-dilutive 18-month loan and extended $500K loan to Sep 2025.
- FDA 510(k) submission for MyoVista wavECG device remains on track for Q1 calendar 2025.
- Cloud-based MyoVista Insights platform Phase 1 on track for end of calendar 2024; FDA submission target H2 2025.
- No revenue reported for Q1 FY2025.

## SEC filing metadata
- accession: 0000950170-24-105923
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017024105923/0000950170-24-105923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017024105923/hscs-20240912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-105923
- JSON: https://secwatch.observer/filing/0000950170-24-105923.json
- Plain text: https://secwatch.observer/filing/0000950170-24-105923.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.